實驗美控 LH 深 滬
已收盤 05-08 16:00:00 美东时间
254.12
-3.930
-1.52%
華盛通- 最 高259.99
- 今 開258.23
- 成交量 58.13万股
- 最 低 252.65
- 昨 收 258.05
- 總市值 2083.78万
- 52周最高 292.28
- 市盈率 靜 24.30
- 換手率 708.88%
- 52周最低 236.87
- 委 比 60.00%
- 總股本 8.20万
- 歷史最高 292.28
- 量 比 0.67
- 振 幅 2.84%
- 歷史最低 29.04
- 每 手 1
- 風險率 11.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | 实验美控 2026财年Q1营收35.38亿美元，同比增长5.8%；归母净利润2.78亿美元，同比增长30.5%
华盛资讯5月5日讯，实验美控公布2026财年Q1业绩，公司Q1营收35.38亿美元，同比增长5.8%，归母净利润2.78亿美元，同比增长30.5%。
05-05 02:32
电话会总结 ｜ Labcorp(LH)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Labcorp 2026年第一季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **整体企业表现：** - 企业总收入达到35亿美元，同比增长5.8% - 调整后营业利润率扩大至14.4%，较上年同期提升超过30个基点 - 调整后每股收益为4.25美元，同比增长10.6% - 自由现金流为7,100万美元，而上年同期为现金流出1.08亿美元 **分部门表现：** - 诊断实验室收入28亿美元，同比增长5% - 生物制药实验室服务(BLS)收入7.81亿美元，同比增长8.2% - 诊断部门调整后营业利润率为16.6%，较上年同期16.
05-01 12:03
Labcorp Advances As AI Investments, Core Businesses Drive Growth
Labcorp shares rise after Q1 earnings beat and higher guidance, supported by diagnostics growth and investments in AI and robotics.
05-01 00:05
财报速睇 | 实验美控 2026财年Q1营收35.38亿美元，同比增长5.8%；归母净利润2.78亿美元，同比增长30.5%
华盛资讯4月30日讯，实验美控公布2026财年Q1业绩，公司Q1营收35.38亿美元，同比增长5.8%，归母净利润2.78亿美元，同比增长30.5%。
04-30 21:47
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.55-$18.25 to $17.70-$18.35 vs $17.87 Est
Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.55-$18.25 to $17.70-$18.35 vs $17.87 analyst estimate..
04-30 18:53
Laboratory Corp Q1 Adj. EPS $4.25 Beats $4.09 Estimate, Sales $3.538B Beat $3.505B Estimate
Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.25 per share which beat the analyst consensus estimate of $4.09 by 3.91 percent. This is a 10.68 percent increase over earnings of $3.84 per share from the same
04-30 18:52
Labcorp Launches Nationwide Rollout Of Agilent's PD-L1 IHC 22C3 pharmDx, The Only FDA-Approved Companion Diagnostic To Identify Patients With Platinum-Resistant Ovarian Cancer Who May Be Eligible For Merck's KEYTRUDA
KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with
04-22 19:11
Labcorp Holdings declares $0.72 dividend
Labcorp Holdings (LH) declares $0.72/share quarterly dividend, in line with previous. Forward yield 1.05% Payable June 11; for shareholders of record May 29; ex-div May 29. See LH Dividend Scorecard, ...
04-09 19:03
